UHUlrich Herrlinger

Ulrich Herrlinger

*This is an algorithmically generated author record based on publicly available information.

Ulrich Herrlinger has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    OS2.1 Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network

    by O Bähr, B Hentschel, E Hattingen, M Reusche, M Tatagiba, J Tonn, O Schnell, G Schackert, M Westphal, U Herrlinger, et al.

    Outside of clinical trials, the occurrence of objective responses (OR) to chemotherapy in patients with recurrent gliomas is poorly characterized. Further, the predictive value of OR for progression-free survival (PFS) and overall survival (OS) in glioma patients is unclear. We screened the German Glioma Network Database for patients who had received any chemotherapy for recurrent glioma from 2004–2008. Patients with a prior gross total resection of the recurrent tumor, patients receiving additional radiotherapy for the recurrent tumor and patients with spinal gliomas were excluded. As PFS was not available for a large number of patients we used the composite endpoint time-to-treatment-failure (progressive disease, start of a new therapy or death). We included 485 patients who received 646 chemotherapy regimens for treatment of recurrent glioma. Of these, only 32 chemotherapies in 32 patients resulted in an objective response (30 PR, 2 CR) after central neuroradiological review according to RANO criteria. OR rates were 2.8%, 11.0% and 10.6% for glioblastoma, anaplastic glioma WHO grade III and diffuse glioma WHO grade II, respectively. Temozolomide (n=232) resulted in ORs in 7.8% of the patients, while nitrosourea (n=212) and imatinib (n=27) resulted in ORs in 6.1% and 3.7%, respectively. Overall, responders showed a significantly improved OS compared to non-responders (median OS 33.3 versus 15 months, p=0.054). Yet, a Cox regression analysis adjusted for diagnosis (including WHO grade) and age did not reveal a significant association of objective responses with overall survival (relative risk 0.8, p=0.391). In addition, we generated a 1:3 cohort (n=96) of non-responders matched for histology and WHO grade. There was no relevant difference in OS comparing responders to the matched cohort (median OS 33.3 versus 25.6 months, p=0.929). When comparing non-responders with longer time-to-treatment-failure (>14 weeks, assumed stable disease as best response) with responders (n=32) the difference in outcome was lost (median OS 24.3 versus 33.3 months, p=0.86). In contrast, non-responders with shorter time-to-treatment-failure (<14 weeks, assumed progressive disease as best response) had dramatically shorter survival (median OS 6.4 versus 33.3 months, p<0.05). In this large, prospective study objective responses to chemotherapy in the recurrent setting were rare in glioma patients. Notably, when comparing responders with a matched cohort or patients with assumed stable disease as best response, objective responses do not seem to be associated with improved survival.

  • P01.013 Long-term analyses of the NOA-08 randomized phase III trial of temozolomide versus radiotherapy for elderly patients with malignant astrocytomas

    by A Wick, T Kessler, M Platten, C Meisner, M Bamberg, U Herrlinger, J Felsberg, A Weyerbrock, C Seidel, J P Steinbach, et al.

    While the NOA-08 trial and the NORDIC Elderly trial suggested an O6-methylguanine DNA-methyl transferase (MGMT) status-tailored use of radiotherapy (RT) and temozolomide (TMZ), recent data from the NCIC CE.6/EORTC 26062 showed that hypofractionated RT plus TMZ was superior to RT for unselected elderly patients with an impact of MGMT for the effect of TMZ. This is the long-term update of the NOA-08 trial (German Cancer Trials Registry ID 386 and NCT01502241) that compared efficacy and safety of RT alone to TMZ alone in elderly patients with anaplastic astrocytoma (AA) or glioblastoma (GB), both isocitrate dehydrogenase wildtype, using overall survival (OS) as primary endpoint and event-free survival (EFS) as well as efficacy according to MGMT status as major secondary endpoints. NOA-08 had randomized patients (N=412; 39 AA, 373 GB) > 65 years with a Karnofsky performance score ≥ 60 in electronically generated blocks of variable length without stratification to receive standard RT to 60 Gy in 30 x 2 Gy fractions or TMZ dosed according to tolerance in a one week on/one week off schedule with tolerability dependent dosing. The trial finished enrolment Nov 2 2009 and demonstrated non-inferiority of TMZ compared with RT (p=0·033). In the long-term analysis with a data cut-off Apr 1 2018 median OS was 8·2 [7·0–10·0] months for TMZ treatment versus 9·4 [8·1–10·4] months for RT; hazard ratio (HR)=0·93 (95% CI: 0·76-1·15)] of TMZ versus RT did not differ between both arms. Also, median EFS [3·4 [3·2–4·1] months versus 4·6 [4·2–5·0] months did not differ with a HR=1·02 (0·83-1·25)]. MGMT promoter methylation tested in tumor tissue (82/221 patients, 37·1%) was associated with prolonged OS [13·6 [10·1–16·5] versus 8·0 [6·9-9·9] months; HR=0·53 (0·40-0·70), pMGMT promoter methylation had longer OS and EFS when treated with TMZ (18·4 [13·9–24·4] months and 8·5 [6·9–13·3] months) versus RT (9·6 [6·4–13·7] months and 4·8 [4·3–6·2] months, HR 0·44 [0.27–0.70], pMGMT promoter methylation had shorter EFS and a shorter OS with the usual testing not significant when treated with TMZ (6·7 [5·6–8·2] months and 3·0 [2·6-3·3] months) versus with RT (10·2 [8·0–12·0] months and 4·6 [3·7-6·4] months), HR 1·33 [0·95-1·87], p=0·099 for OS and 1·86 [1·32-2·62], p<0·001 for EFS). Also in the long-term analyses, NOA-08 confirms the non-inferiority of TMZ compared with RT in the treatment of elderly patients with WHO grade III or IV astrocytic gliomas. To improve OS and EFS, MGMT promoter methylation is a strong predictive biomarker for the choice between RT and TMZ and offers unexpectedly favorable long-term outcome with initial TMZ monotherapy.


  • Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial

    by A. Korfel, L. Fischer, P. Martus, R. Moehle, H. A. Klasen, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, H. Mergenthaler, et al.

    2026 Background: The prognostic impact of MD in PCNSL is still debated. Within the framework of a multicenter randomized trial (G-PCNSL-SG1) we evaluated patients for outcome according to the presence of MD. Methods: Immunocompetent adult patients were initially treated with up to six cycles of high-dose methotrexate (HD-MTX; 4g/m2) based chemotherapy without intrathecal therapy. Those randomized to radiotherapy subsequently received whole-brain radiotherapy (WBRT) with 45 Gy, in 1.5 Gy fractions; those randomized to chemotherapy did not receive further therapy in case of complete remission or high-dose cytarabine when complete response was not achieved. MD was defined by the presence of lymphoma cells in the CSF detected by at least one of the following methods: cytomorphology, detection of clonal B cells by IgH-PCR or contrast enhancement of the leptomeninges on MRI. Results: All 526 patients fulfilling the eligibility criteria were entered into the analysis. MD at presentation was detected in 104 (19.8 %) patients: 95 by cytomorphology, 16 by PCR and 17 by MRI. Pretherapeutic characteristics including age, Karnofsky performance score, sex, serum lactate dehydrogenase, lymphoma localization, mode of biopsy, histology, CSF protein elevation (>45mg/dl) and ocular involvement did not significantly differ in patients with MD and other patients (all p>0.05). Only CSF pleocytosis (>5/µl) was significantly more frequent in patients with MD (37 vs. 14%, p<0.001). The type of chemotherapy (HD-MTX: 83 vs. 75%, HD-MTX and ifosfamide: 17 vs. 25%) applied and the frequency of WBRT (39 vs. 34%) were not significantly different in the group with and without MD. Median overall survival (OAS) in the MD group was 21.5 (95% CI 17.1-25.8) months as compared to 22.4 (17.3-27.5) months in other patients (p=0.8); median progression free survival (PFS) was 6.1 (1.6-10.5) and 7.0 (5.2-8.8) months, respectively (p=0.9). Median OAS and PFS were not significantly different in patients with elevated CSF protein or CSF pleocytosis compared to patients with normal CSF values. Conclusions: MD, elevated CSF protein and CSF pleocytosis had no impact on outcome in this trial.


  • Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1).

    by K. Jahnke, A. Korfel, P. Martus, S. Lokka, R. Moehle, F. Griesinger, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, et al.

    2004 Background: The purpose of this study was to establish prognostic factors in newly diagnosed primary central nervous system lymphoma (PCNSL) in immunocompetent patients. Methods: Four-hundred and eleven patients (median age 63 years, median Karnofsky performance status (KPS) 70%) enrolled in a German multicenter randomized phase III trial (G-PCNSL-SG-1) between May 2000 and May 2009 were analyzed using univariate and multivariate logistic regression analyses to identify prognostic factors for overall response (OR) and progression-free (PFS) and overall survival (OS). Patients were treated upfront with high-dose methotrexate (HDMTX) or HDMTX plus ifosfamide and were whole-brain irradiated thereafter if randomized to radiotherapy and treated with high-dose cytarabine (patients without complete remission) or just followed-up (patients with complete remission) if randomized to chemotherapy alone. Results: On multivariate analysis, female gender (p = 0.003), no corticosteroid medication at study entry (p = 0.003) and p ≥0.01) on multivariate analysis were: HDMTX plus ifosfamide vs. HDMTX monotherapy (for OR), body mass index ≤25 (for OS), <2 tumor lesions (for PFS and OS), and KPS ≥70% (for PFS). Conclusions: This is the first study that established prognostic factors for OR and survival in PCNSL derived from a multicenter, prospective, randomized phase III trial. The data, especially the strong association of age and KPS with OS, should be taken into consideration in the design of future studies in PCNSL.


  • Preliminary results of a Phase II study: combined systemic polychemotherapy and intrathecal treatment with liposomal cytarabine in patients with primary CNS lymphoma ≥60 years

    by A Jürgens, H Pels, M Reiser, A Engert, U Herrlinger, M Lamprecht, G Egerer, M Vogt-Schaden, P Hau, G Schackert, et al.

    Objectives: To evaluate response rate, event free survival, overall survival, and toxicity in primary central nervous system lymphoma (PCNSL) after a combined systemic and intrathecal chemotherapy in patients ≥60 years. Patients and methods: From 11/2005 to 03/2009, 70 patients with PCNSL (median age 67 years) were enrolled in phase II study evaluating systemic polychemotherapy combined with intrathecal application of liposomal cytarabine. All patients were 60 years of age or older at time of diagnosis. A high-dose methotrexate (MTX) (cycles 1,2,4,5) and cytarabine (ara-C) (cycles 3,6) based systemic therapy (including dexamethasone, vinca-alkaloids, ifosfamide and cyclophosphamide) was combined with liposomal cytarabine administered intrathecally via lumbar puncture once during each treatment cycle. Results: Until March 2009, 69 patients were enrolled, 56 were evaluable for response. Of these, 27 (48%) achieved complete response (CR) or unconfirmed complete response (CRu), 8 (14%) partial response (PR), and 10 (18%) progressed under therapy. Six (11%) out of 56 patients died due to treatment-related complications. In five (9%) of 56 patients therapy had do be discontinued due to severe treatment related complications. Follow-up is one to 35 months (median 9 months). Kaplan Meier estimates for median event free survival (EFS) and median progression free survival in responding patients are 9 months, and 14 months, respectively. Median overall survival has not been reached yet. The 5-year survival fraction is 55%. Conclusions: As these preliminary results show, primary chemotherapy based on high-dose MTX and ara-C combined with intrathecal application of liposomal cytarabine is efficient in PCNSL. The results presented are comparable with results from other treatment studies for elderly patients published so far.

  • Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial

    by M. Weiler, C. Hartmann, D. Wiewrodt, U. Herrlinger, J. Schuth, M. Bamberg, A. von Deimling, M. Weller, W. Wick

    2044 Background: To evaluate toxicity and efficacy of an intensified schedule of temozolomide plus indomethacin in addition to standard radiotherapy plus concomitant temozolomide in patients (pts) with newly diagnosed glioblastoma. Methods: This trial (UKT-05) enrolled 41 pts treated with pre-irradiation temozolomide at 150 mg/m² (one week on/one week off), radiotherapy with concomitant temozolomide (50 mg/m²), maintenance temozolomide starting at 150 mg/m² according to an intensified one week on/one week off schedule, plus maintenance indomethacin (25 mg bid) treatment. The primary endpoint was median progression-free survival (PFS). O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation was assessed by methylation-specific PCR in 39 (95.1%) pts. Results: The median follow-up interval is 15.3 months (minimum, 9.4 months). Hematologic grade 3/4 toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE; v3.0) were: anemia (3/41, 7%), leukopenia (9/41, 22%), lymphopenia (26/41, 63%), neutropenia (6/41, 15%), and thrombopenia (8/41, 20%). Treatment-related non-hematologic CTCAE grade 3 through 5 toxicities were reported for n=6/41 (15%) pts. Median PFS was 7.6 months [95% CI, 6.0–9.9 months]. PFS rate at 6 months (PFS-6) was 68.8% [95% CI, 56.3–79.0%]. The censored one year survival rate was estimated at 69.9% [95% CI, 56.8–80.5%]. Median PFS, PFS-6 and median survival time (MST) in 16 pts with MGMT gene promoter methylation were significantly larger than in 23 pts without epigenetic MGMT gene silencing (PFS: 15.8 vs. 6.2 months, p=0.001; PFS-6: 85.8% vs. 59.3%; MST: 24.1+ vs. 12.9+ months, p=0.027). Conclusions: The dose-dense regimen of temozolomide administered in a one week on/one week off schedule resulted in relevant but acceptable toxicity. Compared with data from the EORTC26981/22981/NCIC CE.3 trial, pts with an unmethylated MGMT gene promoter in the tumor did probably not benefit from intensifying the temozolomide schedule regarding median PFS or MST whereas the efficacy in the methylated cohort looks very promising.


  • Phase I/II study (UKT-03) of CCNU/temozolomide chemotherapy in addition to radiotherapy as first-line therapy for glioblastoma: Status report

    by U. Herrlinger, J. Rieger, D. Koch, R.-D. Kortmann, T. Hundsberger, J. Schuth, M. Bamberg, M. Weller

    1566 Background: Primary chemotherapy with single agent temozolomide or nitrosourea-based chemotherapy in addition to radiotherapy prolongs survival in patients with glioblastoma. Previous studies in patients with recurrent gliomas have shown that BCNU, a nitrosourea compound, applied intravenously and oral temozolomide can be safely applied in combination chemotherapy. Methods: This two-center trial accrued patients between November 2002 and December 2003. Patients with newly diagnosed glioblastoma and a Karnofsky performance score of 70% or higher received first-line therapy with 6 courses CCNU 100 mg/m2 (day 1) and temozolomide 100 mg/m2 (days 2–6). The temozolomide dose could be increased to 125 mg/m2/d or 150 mg/m2/d if no myelosuppression had occurred in the previous course. Starting during course 1, all patients also received involved-field radiotherapy with 60 Gy in 2 Gy fractions. All patients were evaluated for toxicity, progression-free survival and overall survival. Results: Thirty-one patients with a median age of 51 years (29–68 years) were treated with a median of 4 courses (range 1–6 courses) of CCNU/temozolomide therapy. WHO grade 4 hematotoxicity was observed in 5 patients. WHO grade 3 or 4 hematotoxicity occurred in 12 patients. One patient died from myelosuppression-associated septicemia. One patient developed WHO grade 4 drug-induced hepatitis. One patient had WHO grade 2 lung fibrosis. After a median follow-up time of 12 months (range 1–25 months), 24 of 31 patients have suffered tumor progression. The median progression-free survival was 9 months with a progression-free survival rate of 61% at 6 months and of 34% at 12 months. So far, 9 patients have died and the median overall survival has not been reached yet. Conclusions: Chemotherapy with CCNU and temozolomide in combination with involved-field radiotherapy is feasible and the progression-free survival of 9 months suggests that this therapy is effective in the primary therapy of glioblastoma.

  • NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report

    by Ulrich Herrlinger, Wilhelm Küker, Martin Uhl, Hans‐Peter Blaicher, Hans‐Otto Karnath, Lothar Kanz, Michael Bamberg, Michael Weller

    The NOA‐03 trial explored high‐dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole‐brain radiotherapy given at relapse (p = 0.11). Attention deficits were found in all six tested patients, and memory deficits in four patients. Two patients had normal, three had moderately restricted, and one had markedly restricted quality of life. Thus, high‐dose methotrexate with deferred radiotherapy had only moderate efficacy and was associated with significant neurotoxicity in long‐term surviving patients. Ann Neurol 2005;57:843–847


  • Relapse of primary CNS lymphoma after more than 10 years in complete remission

    by U. Herrlinger, H. Hebart, L. Kanz, J. Dichgans, M. Weller


  • Adult medulloblastoma

    by Ulrich Herrlinger, A. Steinbrecher, J. Rieger, P. Hau, R.-D. Kortmann, R. Meyermann, M. Schabet, M. Bamberg, J. Dichgans, U. Bogdahn, et al.

    Adult medulloblastoma is a rare tumor with few retrospective studies published so far. The role of adjuvant chemotherapy or chemotherapy at relapse is unclear. This study reports therapy and outcome in all adult (≥ 16 years old) medulloblastoma (n = 34) and supratentorial primitive neuroectodermal tumor (PNET) patients (n = 2) treated in 2 neuro–oncological centers between 1976 and 2002. The median age was 24.5 years (range 16–76). After resection, 16 patients were treated with craniospinal radiotherapy alone, 20 patients also received adjuvant chemotherapy (8 vincristine, CCNU, cisplatin; 7 methotrexate alone or methotrexate/vincristine–based polychemotherapy; 5 other protocols). Median survival in the whole cohort was 126 months (2+ – 200+ months). Five–year and 10–year survival rates were 79 % and 56%. Adjuvant chemotherapy was associated with a non–significant trend to prolonged survival (relative risk (RR) 1.89; p = 0.068). The median progression–free survival (PFS) after primary therapy was 83 months. At relapse, 10 of 12 evaluable patients achieved a complete response upon second–line therapy. The median survival times from first (n = 17) and second relapse (n = 9) were 21 months (0–67+ months; 5/17 without second relapse) and 20 months (1–29 months). Cox regression analysis revealed the infiltration of the floor of the 4th ventricle at diagnosis as the only therapy–independent prognostic factor (RR 0.48; p = 0.03). In conclusion, adjuvant chemotherapy may prolong survival in adult medulloblastoma patients. Moreover, second–line therapy may be beneficial for these patients. As in pediatric medulloblastoma patients, primary infiltration of the floor of the 4th ventricle indicates a poor prognosis.